ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Impact of DAA Treatment on Graft Fibrosis in HCV Positive Liver Transplantation

J. Wellington1, A. Ma2, S. Kottilil3, J. Husson3, E. Wilson3, D. Bruno4

1Gastroenterology & Hepatology, University of Maryland, Baltimore, MD, 2Internal Medicine, University of Maryland, Baltimore, MD, 3Institute of Human Virology, Division of Clinical Care and Research, University of Maryland, Baltimore, MD, 4Transplant Surgery, University of Maryland, Baltimore, MD

Meeting: 2019 American Transplant Congress

Abstract number: D244

Keywords: Fibrosis, Hepatitis C, Liver

Session Information

Session Name: Poster Session D: Non-Organ Specific: Viral Hepatitis

Session Type: Poster Session

Date: Tuesday, June 4, 2019

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall C & D

*Purpose: Liver transplantation, LT, for HCV-related disease has the lowest five-year graft survival of all LT recipients, primarily due to accelerated fibrosis from unrestrained HCV replication. Optimal timing of HCV treatment with direct acting antiviral agents, DAAs, remains unknown. We compared those treated within the first year following LT to those treated before LT to determine if graft fibrosis differs with timing of treatment and LT.

*Methods: We studied HCV LT recipients with sustained viral response, SVR, after DAA treatment before LT or within 1 year of LT. Graft fibrosis was assessed using Fib-4 scores calculated at 1 year after LT if treated before LT and 1 year after SVR if treated after LT. Fib-4 scores &lt 1.45 defined minimal fibrosis.

*Results: We identified 117 LT recipients: 52 treated before LT and 65 treated within 1 year following LT, clinical characteristics in Table 1. Fib-4 scores were &lt 1.45 in 34% of participants overall, 39% of those treated after LT compared to 29% treated before had minimal fibrosis by Fib-4 score, p=0.28. The odds ratio of having minimal fibrosis was 1.54, 95% CI 0.71, 3.37, among those treated within 1 year after LT compared to those treated before LT, p-value 0.23.

*Conclusions: Treatment of HCV before or within one year of LT yields no difference in fibrosis. A third of LT patients had minimal graft fibrosis one year post-SVR, supporting recommendations for early treatment to prevent HCV-related fibrosis.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Wellington J, Ma A, Kottilil S, Husson J, Wilson E, Bruno D. Impact of DAA Treatment on Graft Fibrosis in HCV Positive Liver Transplantation [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/impact-of-daa-treatment-on-graft-fibrosis-in-hcv-positive-liver-transplantation/. Accessed June 5, 2025.

« Back to 2019 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences